title: Pivotal efficacy trials of inhaled corticosteroids in asthma.
abstract: Inhaled corticosteroids (ICSs) are the mainstay of daily controller treatment for persistent and uncontrolled asthma. However, many clinicians are wary of ICSs because of safety concerns. Clinicians need to know the underlying efficacy data that support the use of ICSs to weigh efficacy against safety.
  
  
  
  To discuss efficacy data from pivotal trials to aid clinicians in their decisions to use ICSs.
  
  
  
  Key efficacy studies were selected to augment discussion.
  
  
  
  Clinical studies have revealed that ICSs are effective in reducing the risk of exacerbations in both children and adults. ICSs also reduce the risk of hospitalization and asthma-related death, improve asthma symptoms, and improve quality of life. In addition, ICSs improve lung function and airway responsiveness and reduce airway inflammation and remodeling. In young children, ICSs improve daytime and nighttime symptoms, improve lung function, reduce the risk of exacerbations, and reduce the need for rescue medications. To date, evidence is conflicting about whether intermittent ICS treatment is as effective as daily ICS treatment. The possibility of lower efficacy of intermittent therapy needs to be weighed against a reduced risk of slowed growth in children.
  
  
  
  ICSs effectively reduce the risk of exacerbations, hospitalizations, and asthma-related death and improve asthma symptoms, quality of life, lung function, and airway responsiveness. ICSs also reduce airway inflammation and remodeling. Intermittent therapy may not be as effective as daily therapy, and clinicians should weigh reduced efficacy against reduced risk of adverse effects, particularly slowed growth in children.
authors.affiliation: National Jewish Health, Denver, Colorado. Electronic address: CovarR@njhealth.org.
authors.forename: Ronina A
authors.initials: RA
authors.lastname: Covar
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000367:Age Factors; D056151:Airway Remodeling / Q000187:drug effects; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000066491:Clinical Decision-Making; D002986:Clinical Trials as Topic; D019468:Disease Management; D004359:Drug Therapy, Combination; D006801:Humans; D012129:Respiratory Function Tests; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents